ストックスクリーナーアプリを入手
37.08
6.67%
2.32
アフターアワーズ：
37.08
前日終値:
$34.76
開ける：
$34.95
24時間の取引高:
285.59K
Relative Volume:
0.95
時価総額：
$1.67B
収益：
-
当期純損益:
$-75.27M
株価収益率:
-21.86
EPS:
-1.6963
ネットキャッシュフロー:
$-66.67M
1週間 パフォーマンス:
+7.79%
1か月 パフォーマンス:
-2.50%
6か月 パフォーマンス:
+34.84%
1年 パフォーマンス:
+186.77%
1日の値動き範囲:
$34.95
$38.20
1週間の範囲:
$33.20
$38.29
52週間の値動き範囲:
$7.255
$45.00
Sionna Therapeutics Inc Stock (SION) Company Profile
名前
Sionna Therapeutics Inc
セクター
電話
617-819-2020
住所
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
37.08 | 1.56B | 0 | -75.27M | -66.67M | -1.6963 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Citizens | Mkt Outperform |
| 2025-12-01 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-03 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-04 | 開始されました | Guggenheim | Buy |
| 2025-03-04 | 開始されました | Stifel | Buy |
| 2025-03-04 | 開始されました | TD Cowen | Buy |
すべてを表示
Sionna Therapeutics Inc (SION) 最新ニュース
Setup Watch: Is Sionna Therapeutics Inc currently under institutional pressureTrade Analysis Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? - AOL.com
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Up 3.8%Here's What Happened - MarketBeat
JPMorgan Chase & Co. Lowers Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares - AOL.com
Superstring Capital Invests in Sionna Therapeutics: Q4 2025 Filing DetailsNews and Statistics - IndexBox
'This is one of your classic, binary biotech stocks': Baral on Sionna Therapeutics - BNN Bloomberg
This investor offloaded $5 million worth of a biotech stock that surged 118% over the past year, yet there are still reasons to believe they remain optimistic about its future performance. - Bitget
Braidwell LP Has $9.24 Million Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Health Catalyst (HCAT) - The Globe and Mail
Sionna Therapeutics, Inc. $SION Shares Sold by Atlas Venture Life Science Advisors LLC - MarketBeat
SION: Advancing NBD1 stabilizers for cystic fibrosis with pivotal data expected by mid-2026 - TradingView
Analysts Are Bullish on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Privia Health Group (PRVA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Loss Report: Is now the right time to enter Sionna Therapeutics IncMarket Risk Summary & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Sionna Therapeutics chief legal officer sells shares for $347,018 By Investing.com - Investing.com Australia
Sionna Therapeutics chief legal officer sells shares for $347,018 - Investing.com
TD Asset Management Inc Grows Position in Sionna Therapeutics, Inc. $SION - MarketBeat
Reassessing Sionna Therapeutics (SION) Valuation After Recent Share Price Pullback And CF Pipeline Progress - simplywall.st
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
SION: NBD1 stabilization could transform CF care, with dual and add-on therapies advancing in clinical trials - TradingView
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from BTIG Research - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownShould You Sell? - MarketBeat
Sionna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Guggenheim raises Sionna Therapeutics stock price target to $50 By Investing.com - Investing.com Canada
Sionna Therapeutics Inc maintains strong cash position with about $310.3 million in cash and cash equivalents, expected to fund operations into 2028 - marketscreener.com
Sionna Therapeutics Inc Maintains Strong Cash Position With About $310.3 Million In Cash And Cash Equivalents, Expected To Fund Operations Into 2028 - TradingView
Form S-3ASR Sionna Therapeutics, - StreetInsider
Sionna Therapeutics Q4 Net Loss Narrows - marketscreener.com
Sionna Therapeutics (SION) outlines NBD1-focused cystic fibrosis drug pipeline - Stock Titan
Earnings Flash (SION) Sionna Therapeutics Posts Q4 Net Loss $0.46 a Share, vs. FactSet Est of $0.55 Loss - marketscreener.com
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Sionna Therapeutics 10-K: $0 Revenue, $(1.88) EPS - TradingView
Sionna Therapeutics (Nasdaq: SION) posts 2025 loss, ends year with $310.3M cash - Stock Titan
Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price Momentum - Yahoo Finance
Sionna Therapeutics (NASDAQ:SION) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
JPMorgan Chase & Co. Cuts Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Citizens Initiates Coverage of Sionna Therapeutics (SION) with Market Outperform Recommendation - Nasdaq
Sionna Therapeutics (NASDAQ:SION) Coverage Initiated by Analysts at Citizens Jmp - MarketBeat
Market Recap: Is FIVE in a consolidation phase2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Cystic fibrosis drug developer Sionna heads to key March investor events - Stock Titan
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences - The Manila Times
Sionna Therapeutics, Inc. (SION) Stock Analysis: A High-Stakes Bet on Biotech Innovation with 20.13% Upside Potential - DirectorsTalk Interviews
Is Sionna Therapeutics Inc. still a buy after recent gainsJuly 2025 Trade Ideas & Stepwise Trade Execution Plans - mfd.ru
Fed Meeting: Will Sionna Therapeutics Inc outperform tech stocks2025 AllTime Highs & Community Trade Idea Sharing Platform - baoquankhu1.vn
Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit - Yahoo Finance
2026 Milestones in Focus as Sionna Therapeutics Pursues NBD1 Stabilization for CFTR - AD HOC NEWS
Sionna Therapeutics, Inc. (SION) Investor Outlook: Analyzing a 19% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
SION: NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026 - TradingView
Sionna Therapeutics Inc (SION) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):